Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexavar in chemonaive stage IIIB-IV NSCLC
NCT00300885Phase 3Terminated
- Sponsor
- Bayer
- Start
- Feb 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Sorafenib + C/P with Placebo + C/P (2 arms). Primary endpoint: Overall Survival at 3 months. Started Feb 2006; status: terminated.
02
Drugs
sorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00300885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00300885.